NRIX

Latest SEC Filings & News for NRIX

2 most recent filings and news items mentioning NRIX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/NRIX/news?limit=20"

Pull NRIX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
RegulatoryJun 11, 2026Positive

Nurix reports 92.9% response rate for BTK degrader bexobrutideg in CLL patients

Nurix Therapeutics announced updated Phase 1a/b clinical trial results showing a 92.9% objective response rate in second-line CLL patients treated with bexobrutideg, with durable responses in heavily pretreated patients and promising activity in earlier treatment lines. The posit

View filing at SEC.gov →
M&AJun 8, 2026Positive

Nurix partners with Roche on BTK degrader bexobrutideg for up to $2.3B

Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving $700 million upfront plus up to $2.3 billion in milestone payments. The partnership combines Nurix's protein degradation technology with Roche's clinical expe

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.